Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Acute Myeloid Leukemia Clinical Trial

Official title:

Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03533816
• Other study ID #: IIT-2018-Gamma-DeltaTcell
• Status: Recruiting
• Phase: Phase 1
• Start date: January 31, 2020
• Est. completion date: January 2025

Study information

• Verified date: February 2023
• Source: University of Kansas Medical Center
• Contact: Clinical Trial Nurse Navigator
• Phone: 913-945-7552
• Email: ctnursenav[@]kumc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).

Description:

Many patients with hematological malignancies require a bone marrow transplant for curative treatment. A matched sibling donor is optimal but may not be available. Therefore, a partially matched family member (haploidentical) may be a viable alternative. The incidence of graft vs. host disease, however, can become more of a significant, even fatal, factor with partial matches.

T-cells have been shown to be the key player in the post-transplant immune phenomena. The majority of T-cells are composed of alpha beta T-cells with a small minority of gamma delta T-cells, which are known to have the unique ability to kill malignant cells without antigen recognition.

This study proposes to extract, concentrate, and activate gamma delta T-cells from the peripheral blood to provide innate anti-tumor effect with minimal risk of GVHD. Safety and impact and/or the rate of GVHD will be evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 38
• Est. completion date: January 2025
• Est. primary completion date: January 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

The following criteria are used to enroll patients in the study before transplant.

• Patients with neoplastic hematological disorders with indication of allogeneic transplant according to the National Comprehensive Cancer Network (NCCN) or other standard guidelines as follows:

• Acute myeloid leukemia [AML] in morphologic complete remission with intermediate/high-risk features (per NCCN criteria) or relapsed disease

• Chronic myeloid leukemia [CML] in any chronic phase.

• Myelodysplastic syndrome [MDS] with intermediate/high risk features or refractory disease (with bone marrow blast count <10%).

• Acute lymphoblastic leukemia [ALL] in morphologic complete remission with high-risk features or relapsed disease.

• Negative test for donor-specific antibody within 28 days of starting conditioning regimen.

• Age Criteria: 19-65 years.

• Organ Function Criteria: The following organ function testing should be done within 35 days before study registration.

• Cardiac: Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram.

• Pulmonary: FVC, FEV1 and DLCO (corrected) should be 50% or above of expected.

• Renal: serum creatinine level to be <2 mg/dl AND estimated (Cockcroft-Gault formula) or measured (takes priority if done) creatinine clearance (CrCl) must be equal or greater than 70 mL/min/1.73 m2.

• Hepatic: serum bilirubin 1.5 upper limit of normal (ULN), Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN, and alkaline phosphatase 2.5 ULN.

• Performance status: Karnofsky performance score (KPS) or Lansky score: =80.

• Hematopoietic cell transplant comorbidity index (HCT-CI) <3. Exception may be made on individual cases after discussion with the primary investigator.

• Consent: All patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.

The following criteria are required within 48 hours prior to infusion of the EAGD T cell product.

• Absence of uncontrolled infection with sepsis syndrome (e.g persistent positive blood culture).

• NO hemodynamic instability (due to sepsis or organ dysfunction) or circulatory volume overload.

• NO clinically significant organ toxicity that are defined as follows:

• Heart failure with subnormal LVEF or clinical fluid overload.

• Elevated serum creatinine or subnormal creatinine clearance (either estimated or measured).

• Elevated total bilirubin =1.5 upper normal level (unless indirect hyperbilirubinemia attributed to non-hepatic pathology), or elevated liver enzymes (ALT, AST, ALP) >5 x ULN.

• Hypoxemia requiring oxygen therapy

• NO acute graft versus host disease (any grade).

• Neutrophil engraftment.

Exclusion Criteria:

• Non-compliant patients.

• No appropriate caregivers identified.

• Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician).

• Active central nervous system (CNS) neoplastic involvement.

• Morbid obesity with body mass index >35 (borderline cases may be considered on case-by-case basis after discussion with the primary investigator).

• Patients with known allergy to DMSO.

• HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive.

• Pregnant or breastfeeding women.

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Myelodysplastic Syndromes
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• EAGD T-cell infusion (Phase I)
The Alpha Beta (a/ß) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (?d) enriched cell therapy product.
• EAGD T-cell infusion (Expansion)
The Alpha Beta (a/ß) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (?d) enriched cell therapy product.

Locations

Country	Name	City	State
United States	University of Kansas Cancer Center	Westwood	Kansas

Sponsors (2)

Lead Sponsor	Collaborator
University of Kansas Medical Center	In8bio Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I - Dose-limiting toxicity (DLT)	The dose escalation strategy will follow the Food and Drug Administration Guideline for design of early phase clinical trials of cellular therapy products.	Baseline to Day 30
Primary	Phase I - Severe acute adverse events following infusion of EAGD T-cells	Safety of the infusion will be based on the risk of treatment-related severe adverse events as identified in the National Cancer Common Terminology Criteria for Adverse Events (CTCAE) version 4.	Baseline to Day 100
Primary	Expansion phase - Rate of acute GVHD	Monitoring for GVHD is assessed with Grade II-IV adverse events as identified by the National Cancer Common Terminology Criteria for Adverse Events (CTCAE) version 4.	Baseline to Day 100
Secondary	Expansion phase - Relapse following haploidentical HCT and PTCy with EAGD T-cell infusion	Number of subjects who have acute GVHD by day 100 post-HCT after infusion of EAGD T-cells	Baseline to 100 days
Secondary	Expansion phase - Non-relapse mortality following haploidentical HCT and PTCy with EAGD T-cell infusion	Number of subjects who have no relapse by day 100 post-HCT after infusion	Baseline to 100 days
Secondary	Expansion phase - Overall survival following haploidentical HCT and PTCy with EAGD T-cell infusion	Number of subjects who are living by day 100 post-HCT after infusion	Baseline to 100 days
Secondary	Rate of one-year relapse-free survival (RFS)	Number of subjects living without relapse of disease after one year following HCT	Baseline to one year
Secondary	Rate of one-year non-relapse mortality (NRM)	Number of subjects no longer living but not from disease relapse after one year following HCT	Baseline to one year
Secondary	Rate of one-year overall survival (OS)	Number of subjects living after one year following HCT	Baseline to one year
Secondary	Proportion of subjects with chronic GVHD at one year	Number of subjects with chronic GVHD after one year following HCT	Baseline to one year